Investigation of optimal regimen of Fulvestrant in patients with postmenopausal ER-positive advanced recurrent breast cancer
Latest Information Update: 21 Mar 2023
At a glance
- Drugs Fulvestrant (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms SAFARI
- 07 Mar 2023 Results of an additional analysis (n=279) assessing the factors that influence the time to treatment failure of medroxyprogesterone acetate in real-world settings as late-line treatment, published in the Japanese Journal of Clinical Oncology.
- 31 May 2022 Results (n=598) of an ad hoc analysis assessing relationship between patient factors and overall survival after recurrence published in the Japanese Journal of Clinical Oncology
- 14 Dec 2019 Results of follow up data evaluating relationship between clinicopathological factors and post-recurrence survival (PRS) in ER+ HER2- recurrent breast cancer patients, presented at the 42nd Annual San Antonio Breast Cancer Symposium.